Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001446580-25-000123
Filing Date
2025-11-13
Accepted
2025-11-13 17:45:11
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9101
2 JOINT FILING AGREEMENT nktr_sc13g-ex99.htm EX-99 1474
  Complete submission text file 0001446580-25-000123.txt   12593
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Subject) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-45385 | Film No.: 251480066
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 401 CITY AVENUE, SUITE 220 BALA CYNWYD PA 19004
Business Address 401 CITY AVENUE, SUITE 220 BALA CYNWYD PA 19004 610-617-2600
SUSQUEHANNA SECURITIES, LLC (Filed by) CIK: 0001446580 (see all company filings)

EIN.: 232754552
Type: SCHEDULE 13G